Mid-term Clinical and Radiological Outcomes of Latissimus Dorsi Tendon Transfer in Massive Rotator Cuff Tears

Background This retrospective study was undertaken to evaluate mid-term clinical and radiological outcomes of lattisimus dorsi (LD) tendon transfer in patients with irreparable massive rotator cuff tears (MRCT). We hypothesize that LD tendon transfer would provide safe and satisfactory clinical outcomes at mid-term follow-up. Methods From November 2008 to December 2016, 23 patients (57.5 ± 4.4 years; 20 male, 3 female) who underwent LD tendon transfer for massive tears, were enrolled. Inclusion criteria were irreparable MRCT. Exclusion criteria included full thickness subscapularis tear, rotator cuff arthropathy, anterosuperior rotator cuff tear, and osteoarthritis. Mean follow-up period was 4.7 ± 4.0 years (range, 2–12 years). Clinical assessment (American Shoulder and Elbow Surgeons [ASES], University of California, Los Angeles [UCLA], Simple Shoulder Test [SST]) and radiographic assessment (osteoarthritis [OA], acromiohumeral distance [AHI]) were evaluated. Results ASES, UCLA and SST scores, and range of motion (ROM), except internal rotation, improved significantly at the last follow-up (p<0.05). Also, AHI was significantly improved at the last follow-up, from 6.6 mm to 8.2 mm (p=0.008). At the final follow-up, the radiologic stages of the glenohumeral osteoarthritis were determined as stage 1 in 9 patients, stage 2 in 10 patients, stage 3 in 2 patients, and stage 4 in 2 patients. Complications were observed in 21.7% cases: 3 re-tears and 2 infections were noted in our study. Conclusions LD tendon transfer for irreparable MRCT provides satisfactory clinical outcomes at mid-term follow-up. Mild degenerative osteoarthritis (stage 1, 2) of the shoulder joint are common at the mid-term follow-up. Also, complications such as tear, infection should be considered

Discovery of common Asian copy number variants using integrated high-resolution array CGH and massively parallel DNA sequencing

Copy number variants (CNVs) account for the majority of human genomic diversity in terms of base coverage. Here, we have developed and applied a new method to combine high-resolution array comparative genomic hybridization (CGH) data with whole-genome DNA sequencing data to obtain a comprehensive catalog of common CNVs in Asian individuals. The genomes of 30 individuals from three Asian populations (Korean, Chinese and Japanese) were interrogated with an ultra-high-resolution array CGH platform containing 24 million probes. Whole-genome sequencing data from a reference genome (NA10851, with 28.3x coverage) and two Asian genomes (AK1, with 27.8x coverage and AK2, with 32.0x coverage) were used to transform the relative copy number information obtained from array CGH experiments into absolute copy number values. We discovered 5,177 CNVs, of which 3,547 were putative Asian-specific CNVs. These common CNVs in Asian populations will be a useful resource for subsequent genetic studies in these populations, and the new method of calling absolute CNVs will be essential for applying CNV data to personalized medicine.Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516Kim JI, 2009, NATURE, V460, P1011, DOI 10.1038/nature08211Horowitz RE, 2008, NEW ENGL J MED, V359, P2393Shiffman D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002895Kidd JM, 2008, NATURE, V453, P56, DOI 10.1038/nature06862Perry GH, 2008, AM J HUM GENET, V82, P685, DOI 10.1016/j.ajhg.2007.12.010Graham DSC, 2008, GENES IMMUN, V9, P93, DOI 10.1038/sj.gene.6364453Lohmueller KE, 2008, NATURE, V451, P994, DOI 10.1038/nature06611Korbel JO, 2007, SCIENCE, V318, P420, DOI 10.1126/science.1149504Hossain P, 2007, NEW ENGL J MED, V356, P213Larson MG, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S5Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329Jee SH, 2006, NEW ENGL J MED, V355, P779Aitman TJ, 2006, NATURE, V439, P851, DOI 10.1038/nature04489Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697Wang YH, 2005, J LAB CLIN MED, V146, P321, DOI 10.1016/j.lab.2005.07.007Lindner I, 2005, MOL NUTR FOOD RES, V49, P972, DOI 10.1002/mnfr.200500087Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502Burchard EG, 2003, NEW ENGL J MED, V348, P1170COLIN Y, 1991, BLOOD, V78, P27474